PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
GlobalData has released its new Coun...
3 Introduction 7
3.1 Catalyst 7
3.2 Related Reports 8
3.3 Upcoming Related Reports 10
4 Disease Overview 10
4.1 Etiology A...
7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
Markets 47
8 Pipel...
We serve all sizes and types of companies spanning across various industries.
Contact:
M/s Sheela,
90 State Street,
Suite ...
Upcoming SlideShare
Loading in...5
×

Latest Pharma Report: meningococcal vaccines - spain drug forecast and market analysis to 2022

153

Published on


PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170315
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
153
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Latest Pharma Report: meningococcal vaccines - spain drug forecast and market analysis to 2022

  1. 1. PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Spain Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, GlobalData believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013). Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in Spain from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in Spain table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executive Summary 4 2.1 Sales For Meningococcal Vaccine In Spain 4 PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
  2. 2. 3 Introduction 7 3.1 Catalyst 7 3.2 Related Reports 8 3.3 Upcoming Related Reports 10 4 Disease Overview 10 4.1 Etiology And Pathophysiology 11 4.1.1 Etiology 11 4.1.2 Pathophysiology 12 4.2 Symptoms 13 4.3 Prognosis 14 5 Disease Management 14 5.1 Meningococcal Immunization Policy 15 5.2 Spain 17 5.2.1 Meningococcal Immunization Recommendations And Policies 17 5.2.2 Clinical Practice 17 6 Competitive Assessment 19 6.1 Overview 19 6.2 Strategic Competitor Assessment 19 6.3 Product Profiles Major Brands 20 6.3.1 Menveo 20 6.3.2 Nimenrix 23 6.3.3 Meningitec 25 6.3.4 Menjugate 28 6.3.5 Neisvac-c 31 6.3.6 Bexsero 34 7 Opportunity And Unmet Need 36 7.1 Overview 36 7.2 Unmet Needs 37 7.2.1 Unmet Need: Protection Against Serogroup B Disease 37 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 37 7.2.3 Unmet Need: More Cost-effective Vaccines 39 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 39 7.2.5 Unmet Need: Immunogenic Infant Vaccines 41 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 42 7.2.7 Unmet Need: Increased Patient Awareness And Education 43 7.3 Unmet Needs Gap Analysis 44 7.4 Opportunities 45 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 45 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 46 PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
  3. 3. 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 47 8 Pipeline Assessment 47 8.1 Overview 47 8.2 Promising Vaccines In Clinical Development 47 8.2.1 Mnb Rlp2086 51 8.3 Promising Vaccines In Early Clinical Development 56 8.3.1 Meninge Acyw Conj. 56 8.3.2 Menabcwy 60 8.3.3 Menc Conjugate 63 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 66 9 Market Outlook 68 9.1 Spain 68 9.1.1 Forecast 68 9.1.2 Key Events 71 9.1.3 Drivers And Barriers 72 10 Appendix 74 10.1 Bibliography 74 10.2 Abbreviations 84 10.3 Methodology 86 10.4 Forecasting Methodology 86 10.4.1 Vaccine Coverage 87 10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 87 10.4.3 Vaccines Included 88 10.4.4 Key Launch Dates 89 10.4.5 General Pricing Assumptions 90 10.4.6 Individual Vaccine Assumptions 91 10.4.7 Pricing Of Pipeline Agents 96 10.5 Physicians And Specialists Included In This Study 97 10.6 About The Authors 100 10.6.1 Authors 100 10.6.2 Reviewers 100 10.6.3 Global Head Of Healthcare 100 10.7 About Globaldata 101 10.8 Contact Us 101 10.9 Disclaimer 101 Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
  4. 4. We serve all sizes and types of companies spanning across various industries. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

×